Recursion Pharmaceuticals rises as positive Phase 1b/2 trial results for REC-4881 validate AI-driven drug discovery platform

Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) is one of the most active US stocks to buy according to analysts. On December 8, ...
Yahoo Finance

Recursion (RXRX) Up on $50M NVDA Investment for AI Drug Discovery

Recursion Pharmaceuticals RXRX announced a significant investment worth $50 million from NVIDIA Corporation NVDA, a renowned technology company specializing in accelerated computing. This investment ...
The Motley Fool

Is Recursion Pharmaceuticals a Buy Ahead of Its Merger With Exscientia?

On Aug. 8, Recursion Pharmaceuticals announced its intention to merge with Exscientia in an all-stock deal. Recursion Pharmaceuticals and Exscientia are both pharma-tech companies that aim to improve ...
Yahoo Finance

Recursion Reports Second Quarter 2025 Financial Results and Provides Business Update

SALT LAKE CITY, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, today reported business updates and ...
Forbes

Recursion’s Incoming CEO Needs To Prove That AI Drug Development Can Pay Off

After a challenging 12 years trying to use AI to create new medicines, cofounder Chris Gibson stepped down as CEO last week. Can R&D chief and new CEO Najat Khan turn it around? In 2014, Recursion ...
FierceBiotech

Several months after Exscientia merger, AI biotech outfit Recursion reworks pipeline

Evidently in the mood for some spring cleaning, Salt Lake City’s Recursion is clearing out a chunk of its pipeline as it narrows its focus on R&D in oncology and rare diseases. The move comes roughly ...
FierceBiotech

Recursion lays off 20% of staff in wake of pipeline cutbacks

Recursion Pharmaceuticals is laying off a fifth of its workforce in connection with a previously announced streamlining of the AI biotech’s pipeline. Shrinking the Salt Lake City-based company’s ...